Since the completion of my clinical training a decade ago, my research has focused on the question, """"""""Why do some patients with Staphylococcus aureus infection do well, while others do poorly?"""""""" Recently, I have come to a distinct crossroad as a physician-scientist. I have erected a research infrastructure which is well-funded and has a breadth of research activities. While focused on S. aureus, it spans from the basic science of the organism's pathogenesis, to host genetic susceptibility, to direct clinical features of disease. I am in an institutional environment which allows me to tap into its substantial resources of training and trainees. I have also demonstrated a track record in providing mentorship to a wide variety of beginning researchers. For these reasons, I believe it is critically important for me to earn a K24 so I can focus on research and its mentoring and avoid the common pitfall of the physician/scientist who becomes clinically overcommitted. Thus, the overall goal of this proposal is to improve my mentoring skills by training the next generation of clinician-scientists in clinical and translational patient oriented research in the staphylococci. Mentoring skills are not innate;they can and should be learned. I will develop my mentoring expertise in several ways. First, my mentoring progress will receive regular formal review from an Advisory Board of senior researchers and mentors. Next, I will create the """"""""Mentoring Mid-Career Mentors Program"""""""". In contrast to the senior-level input outlined above, this program will pursue a """"""""peer to peer"""""""" approach to mentor skills development by bringing together Duke's mid-career K24 recipients to discuss common mentoring issues. Finally, I will participate in mentoring on a national level by involvement in the National Subcommittee on Mentoring of the Duke CTSA. Scientifically, I will facilitate my mentoring plan by pursuing two Specific Aims that incorporate the breadth of my research platform.
Each Aim i ncludes several distinct projects focused on patient oriented research of staphylococci. These projects will serve as the hypothesis-testing science that undergirds my mentoring plan.
Specific Aim 1, mentoring clinical patient oriented research in staphylococci, will be accomplished by pursuing 3 individual projects: one project focused on a randomized, multinational trial of a treatment algorithm for catheter-related staphylococcal bacteremia, and two other projects employing large clinical databases of staphylococcal infections.
Specific Aim 2, mentoring translational patient-oriented research in staphylococci, will be accomplished by pursuing several projects involving bacterial and host genetic determinants of S. aureus infection. My long-term objective is to create a multidisciplinary program that focuses on clinical and translational POR of staphylococci. By expanding the breadth of my research program, a K24 would enhance my progress towards this goal, and would help to prepare the next generation of clinician-scientists to confront this persistent pathogen.

Public Health Relevance

OF THIS PROPOSAL TO PUBLIC HEALTH: This K24 proposal is highly relevant to the health of the American Public, as it aims to prepare the next generation of clinician-scientists to confront Staphylococcus aureus. S. aureus is one of the leading pathogens plaguing the American public. Rates of both infections and antibiotic resistance in S. aureus are increasing. The identification of clinical S. aureus isolates resistant to available antibiotics indicates the possibility of a pathogen resistant to all currently approved therapy. This proposal seeks to improve our understanding of this persistent pathogen by mentoring young investigators in clinical and translational patient oriented research of staphylococci.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AI093969-04
Application #
8606149
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Huntley, Clayton C
Project Start
2011-03-05
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
4
Fiscal Year
2014
Total Cost
$138,832
Indirect Cost
$10,284
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Maskarinec, Stacey A; Parlak, Zehra; Tu, Qing et al. (2018) On-demand release of Candida albicans biofilms from urinary catheters by mechanical surface deformation. Biofouling 34:595-604
Holland, Thomas L; Raad, Issam; Boucher, Helen W et al. (2018) Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. JAMA 320:1249-1258
Lantos, Paul M; Tsao, Jean; Nigrovic, Lise E et al. (2017) Geographic Expansion of Lyme Disease in Michigan, 2000-2014. Open Forum Infect Dis 4:ofw269
Rojas, Laura J; Salim, Madiha; Cober, Eric et al. (2017) Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clin Infect Dis 64:711-718
Henig, Oryan; Cober, Eric; Richter, Sandra S et al. (2017) A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. Open Forum Infect Dis 4:ofx157
Thaden, Joshua T; Li, Yanhong; Ruffin, Felicia et al. (2017) Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrob Agents Chemother 61:
Eilertson, Brandon; Cober, Eric; Richter, Sandra S et al. (2017) Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. Open Forum Infect Dis 4:ofx216
Thaden, Joshua T; Park, Lawrence P; Maskarinec, Stacey A et al. (2017) Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria. Antimicrob Agents Chemother 61:
Pericàs, J M; Messina, J A; Garcia-de-la-Mària, C et al. (2017) Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal ?-lactam antibiotics: a prospective cohort study by the Internationa Clin Microbiol Infect 23:544-549
Holland, Thomas L; Baddour, Larry M; Bayer, Arnold S et al. (2016) Infective endocarditis. Nat Rev Dis Primers 2:16059

Showing the most recent 10 out of 66 publications